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Performance Evaluation of a New Automated 
Chemiluminescent Immunoanalyzer-Based Interferon-
Gamma Releasing Assay AdvanSure I3 in Comparison 
With the QuantiFERON-TB Gold In-Tube Assay
Jin Ju Kim , M.D., Younhee Park , M.D., Ph.D., Dasom Choi , M.T., and Hyon-Suk Kim , M.D., Ph.D. 
Department of Laboratory Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea 
Background: The interferon-gamma (IFN-γ) releasing assay (IGRA) is widely used for la-
tent tuberculosis infection (LTBI) diagnosis. We evaluated the analytical performance of a 
new automated chemiluminescent immunoanalyzer-based IGRA (CLIA-IGRA), AdvanSure 
I3 (LG Life Sciences, Seoul, Korea) and compared it with that of the QuantiFERON-TB 
Gold In-Tube (QFT-GIT) assay. 
Methods: Repeatability and reproducibility were evaluated at four levels. Detection capa-
bility, including limit of blank (LoB), limit of detection (LoD), and limit of quantification (LoQ), 
was evaluated using IFN-γ standard material (National Institute for Biological Standards 
and Control code: 87/586). Agreement between the results of two assays was evaluated 
using 341 blood samples from healthcare workers and patients at a tertiary care hospital. 
To determine the cut-off value of CLIA-IGRA for diagnosing LTBI, the ROC curve was ana-
lyzed.
Results: Repeatability and reproducibility were 4.86–7.00% and 6.36–7.88% CV, respec-
tively. LoB, LoD, and LoQ were 0.022, 0.077, and 0.249 IU/mL, respectively. IFN-γ values 
between CLIA-IGRA and QFT-GIT showed a strong correlation within the analytical mea-
surable range of both assays, especially when the value was low. Qualitative comparison 
of the two assays yielded a 99.1% overall agreement (kappa coefficient=0.98). A cut-off 
value of 0.35 IU/mL was appropriate for diagnosing LTBI.
Conclusions: CLIA-IGRA is a reliable assay for LTBI diagnosis, with performance similar to 
that of QFT-GIT. 
Key Words: Performance, Interferon-γ releasing assay, Latent tuberculosis infection, Che-
miluminescent immunoanalyzer, QuantiFERON-TB Gold In-Tube 
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INTRODUCTION
Tuberculosis (TB) is one of the most important chronic diseases, 
causing significant mortality and morbidity in immunocompro-
mised patients worldwide. Korea is one of the top 30 countries 
with a high TB burden [1]. TB develops in only 5–10% of peo-
ple exposed to the pathogen; the remaining 90% become la-
tently infected for life without developing active TB. Latent TB 
infection (LTBI) is a clinical state that is currently defined by im-
munological evidence of Mycobacterium tuberculosis infection 
accompanied by the absence of clinical and radiographic evi-
dence of TB-related symptoms and pathology [2]. As 5–15% of 
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LTBIs are known to be active, it is important to diagnose LTBI as 
well as acute TB [3]. In Korea, screening for LTBI using the tu-
berculin skin test (TST) and/or an interferon gamma (IFN-γ) re-
leasing assay (IGRA) has been performed in high-risk groups, 
such as military personnel, school children, anti-tumor necrosis 
factor users, and healthcare workers (HCWs), as a governmen-
tal policy since 2017 [4]. 
Two IGRAs have been approved by the US Centers for Dis-
ease Control and Prevention (CDC) for diagnosing LTBI: the Quanti-
FERON-TB Gold In-Tube (QFT-GIT) assay (Qiagen, Germantown, 
MD, USA) and the T-SPOT-TB assay (Oxford Immunotec, Ox-
ford, UK) [5]. The QFT-GIT assay is a whole-blood IGRA using 
M. tuberculosis-specific synthetic antigens, early secreted anti-
genic target 6 (ESAT-6), culture filtrate protein 10 (CFP-10), and 
TB 7.7, which stimulate T lymphocytes to release IFN-γ [6]. QFT-
GIT assay results are more reliable than TST results, with a higher 
sensitivity and stronger correlation with exposure to M. tubercu-
losis [7, 8]. Although QFT-GIT assay has several advantages over 
the TST, this assay uses microplate ELISA, which has some dis-
advantages in clinical laboratories such as labor-intense and 
time-consuming steps and the need for standard serial dilutions 
for every microplate. Therefore, a Korean manufacturer (LG Life 
Sciences, Seoul, Korea) has developed a simple, automated che-
miluminescent immunoanalyzer (CLIA), AdvanSure I3, to mea-
sure IFN-γ levels for IGRA. This new format has several advan-
tages such as ease of use for small assay volumes, rapid turn-
around time, high analytical measurement ranges, and good pre-
cision. We compared the results of this new simple automated 
CLIA-IGRA with those of the classic QFT-GIT assay. This is the 
first study to evaluate the analytical performance of CLIA-IGRA.
METHODS
Samples
This study involved a short-term prospective analysis carried out 
at Severance Hospital, Seoul, Korea. We used 341 non-dupli-
cated blood samples obtained from HCWs (n=283) and patients 
(n=58) screened for LTBI and TB infection from June to July 
2017. This study was approved by the Institutional Review Board 
(IRB) of Yonsei University Health System, Severance Hospital, 
Seoul, Korea, and informed consent was obtained from all sub-
jects (IRB 1-2017-0066).
IGRA 
Blood sample collection, tube distribution, mixing, and incuba-
tion were simultaneously performed using the processes of both 
assays. A total of 12 mL of blood was drawn into two lithium hep-
arin tubes, one for CLIA-IGRA and the other for QFT-GIT assay. 
We distributed the samples in 1-mL aliquots into each set of 
manufacturer-specific tubes within six hours: negative control 
(NC), TB antigens, and positive control (PC) tubes. The assay 
tubes were inverted at least 10 times to allow for sufficient mix-
ing of the blood sample with the antigens attached to the tube 
wall. After mixing, sample tubes were kept upright and incu-
bated within one hour. Tubes were handled at a temperature 
range of 17–25°C before incubation. After incubation for 16–24 
hours at 37°C, samples were immediately centrifuged at 2,000–
3,000×g to separate the plasma. The CLIA-IGRA tubes were 
centrifuged for five minutes and the QFT-GIT assay tubes for 15 
minutes.
AdvanSure I3 (LG Life Sciences) is a one-step sandwich CLIA 
designed to quantitatively detect IFN-γ using an automated ana-
lyzer. Fifty microliters of incubated plasma from each of the three 
tubes were placed into the CLIA-IGRA analyzer cartridge. Three 
cartridges per subject were run together in the analyzer; the quan-
titative results of each tube along with the interpretation (positive 
or negative for TB infection) were displayed after 15 minutes. A 
pair of anti-human IFN-γ (anti-hIFN-γ) antibodies was used for 
detection: magnetic particles coated with an anti-IFN-γ antibody 
captured IFN-γ from the sample and an acridinium-conjugated 
anti-hIFN-γ antibody attached to the IFN-γ-antibody complex. 
The intensity of the chemiluminescent signal was calculated as 
relative light unit (RLU), which correlated to the amount of IFN-γ. 
The assay was calibrated against non-WHO reference material, 
IFN-γ (National Institute for Biological Standards and Control 
[NIBSC] code: 87/586).
The CLIA-IGRA results were compared with those of QFT-GIT 
assay. QFT-GIT assay was performed manually, and detection 
was performed using BEP III (Siemens, Marburg, Germany). 
Qiagen Analysis Software (version 2.50) was used for data cal-
culation. A duplicated four-point standard curve was used for 
QFT-GIT assay using standard material (8.0 IU/mL) provided 
with the QFT-GIT assay kit.
Results from both assays were interpreted as follows: positive, 
NC value was ≤8.0 IU/mL and the TB antigen minus the NC 
IFN-γ value was ≥0.35 IU/mL and ≥25% of the NC value; neg-
ative, the PC-NC value was >0.5 IU/mL, the NC value was <8.0 
IU/mL, and the TB antigen minus the NC IFN- γ value was <0.35 
IU/mL or ≥0.35 IU/mL and ≥25% of the NC value. Other con-
ditions were considered indeterminate. All experiments were 
performed according to the manufacturers’ instructions. The 
characteristics of each assay are compared in Table 1. 
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Analytical evaluation
The analytical performance of CLIA-IGRA was evaluated accord-
ing to the CLSI EP5-A3 protocol for precision [9]. Precision pro-
file was estimated by analyzing four samples diluted with the 
IFN-γ standard and negative material control (human plasma, 
ID: 23197-PJ; PlasmaLab International, Everett, WA, USA) in 
two runs per day, two replicates per run, for a total of 20 days 
(N=80) at two different sites. Repeatability was calculated based 
on the results obtained by assaying replicates for a given sample 
in a single run. Data were expressed as CV and reported as per-
centage (%); the acceptable criterion for total % CV was consid-
ered <10%.
The CLSI EP17-A2 protocol was used to determine limit of 
blank (LoB), limit of detection (LoD), and limit of quantification 
(LoQ) [10]. LoB was obtained by assaying an IFN-γ-negative so-
lution 84 times and calculated as the value of the 95th ranked 
sample. LoD was determined by assaying four IFN-γ sample 
pools with very low IFN-γ levels (0.12–0.15 IU/mL) 80 times; the 
LoD was calculated for each level, and the highest value among 
the samples was chosen. LoQ was calculated using eight very 
low to low IFN-γ level samples (0.12–2.5 IU/mL) and determined 
as the highest level with a total error of <10%. 
Using the diluted IFN-γ standard, we obtained serial dilutions 
within a set range (0.25–200 IU/mL), and two determination 
replicates were performed for recovery analysis. Recovery per-
centage was calculated by dividing the mean observed value by 
the mean expected value.
The CLSI EP12-A2 protocol was used for comparing positive 
or negative results [11]. For discordant results between the two 
assays, we repeated both assays and reviewed the medical re-
cords of the subjects (for age, sex, TB infection history, TST re-
sults, chest X-ray, and TB-PCR) to evaluate which assay results 
were consistent with the subjects’ clinical status.
The CLSI EP09-A3 protocol was used for comparing the quan-
titative IFN-γ values of the CLIA-IGRA to those of QFT-GIT assay 
as a reference method [12]. Among the 341 samples, 38 sam-
ples with IFN-γ values >10 IU/mL by QFT-GIT and >100 IU/mL 
by CLIA-IGRA were excluded as these values were above the 
analytical measurement range of each assay. Thus, a total of 
303 blood samples were compared. Comparisons were also 
performed in subgroups with samples with a background-cor-
rected TB antigen QFT-GIT value <5, <2, or <1 IU/mL to de-
termine the correlation near the cut-off value (0.35 IU/mL).
Statistical analysis 
Statistical analysis was performed using Microsoft Excel (Micro-
soft Corporation, Redmond (WA), USA) and Analyse-it Method 
Evaluation Edition version 5.11 software (Analyze-it Ltd., Leeds, 
UK). The correlation between the IFN-γ values of the TB antigen 
tube obtained by CLIA-IGRA and QFT-GIT assay was evaluated 
using the Passing–Bablok model and Pearson’s correlation co-
efficient (R). Cut-off value of CLIA-IGRA was validated by ROC 
curve analysis assuming the positive result of the reference 
method, QFT-GIT assay, as true acute TB or LTBI. Area under 
the curve (AUC) was reported with 95% confidence interval (CI). 
Kappa values of <0.40, 0.40 to <0.60, 0.60 to <0.80, and 
>0.80 were interpreted as fair, moderate, substantial, and near 
perfect agreement, respectively [13]. P <0.05 was considered 
statistically significant.
Table 1. Comparison of assay characteristics
Characteristics CLIA-IGRA QFT-GIT assay 
Peptide used ESAT-6, CFP-10, TB7.7 ESAT-6, CFP-10, TB7.7
Incubation temperature and time 37°C, 16–24 hours 37°C, 16–24 hours
Minimum sample volume required 50 µL 50 µL
Centrifugation conditions for plasma harvesting 2,000×g, 5 minutes 2,000–3,000×g, 15 minutes
Time to obtain results* 15 minutes 2 hours 30 minutes
Analytical measurement range 0–100 IU/mL 0–10 IU/mL
Number of samples per run 2 samples/machine (8 wells) 29 samples/ microplate (96 wells) 
Assay type CLIA ELISA
Assay platform Automated Automated/Manual
*Time after incubation.
Abbreviations: TB, tuberculosis; ESAT-6, early secreted antigenic Target 6; CFP-10, culture filtrate protein 10; CLIA, chemiluminescence immunoassay; 
CLIA-IGRA, chemiluminescent immunoanalyzer-based IGRA; QFT-GIT, QuantiFERON-TB Gold In-Tube.
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RESULTS
Analytical characteristics of CLIA-IGRA
The target values of the control materials were 1.05, 2.47, 34.30, 
and 90.21 IU/mL, and the repeatability and within-laboratory 
precision showed a % CV of 4.86–7.00% and 5.43–7.80%, re-
spectively. Reproducibility showed a % CV of 6.36–7.88%, which 
met the criterion of % CV<10% (Table 2). The LoB, LoD, and 
LoQ values were 0.02, 0.07, and 0.25 IU/mL, respectively. To 
evaluate dilution linearity, a serial dilution from 200 to 0.25 IU/
mL was performed, and the recovery percentage ranged from 
92.57% to 109.51%. 
Comparison of results between CLIA-IGRA and QFT-GIT 
assay
The CLIA-IGRA showed near perfect agreement (kappa=0.98) 
with QFT-GIT assay and had an overall agreement of 338/341 
(99.12%) among all samples (Table 3). There were three dis-
cordant samples with negative CLIA-IGRA and positive QFT-GIT 
assay results. To confirm the discrepancy in these three sam-
Table 2. Total precision of chemiluminescent immunoanalyzer-based interferon gamma releasing assay
Samples Site
Target 
value  
(IU/mL)
Mean 
value  
(IU/mL)
Repeatability Between-Run Between-Day Within-lab Reproducibility
SD % CV SD % CV SD % CV SD % CV SD % CV
1 1 90.21 86.49 4.20 4.86 4.67 5.40 3.73 4.31 5.80 6.70 5.46 6.36
2 85.12 4.91 5.77 3.37 3.96 2.70 3.18 5.01 5.88
2 1 34.30 37.14 2.34 6.30 1.86 5.01 1.39 3.75 2.53 6.82 2.74 7.55
2 35.33 2.18 6.18 1.55 4.39 1.37 3.89 2.34 6.62
3 1 2.47 2.38 0.13 5.60 0.10 4.11 0.05 2.31 0.13 5.43 0.17 7.24
2 2.25 0.13 5.79 0.10 4.49 0.08 3.76 0.14 6.40
4 1 1.05 1.07 0.07 7.00 0.06 5.69 0.05 4.48 0.08 7.80 0.08 7.88
2 1.02 0.05 4.99 0.04 3.70 0.05 4.45 0.06 6.25
Abbreviation: % CV, coefficient of variation expressed as percentage.
Table 3. Qualitative comparison of CLIA-IGRA and QFT-GIT assay results in health care workers and patients (N=341)
CLIA-IGRA
QFT-GIT % Agreement (95% CI)
Kappa  
coefficientPositive 
(N=197)
Indeterminate 
(N=1)
Negative 
(N=143)
Positive Negative Overall
Positive (N=194) 194 0     0  98.48 (95.25–99.61) 97.95 (93.65–99.47) 99.12 (97.23–99.77) 0.98 (0.96–1.00)
Indeterminate (N=1)     0 1     0
Negative (N=146)     3 0 143
Abbreviations: CLIA-IGRA, chemiluminescent immunoanalyzer-based interferon gamma releasing assay; QFT-GIT, QuantiFERON-TB Gold In-Tube; CI, confi-
dence interval.
Table 4. Clinical information of subjects with discordant CLIA-IGRA and QFT-GIT assay results
Subject
Age (yr)/ 
sex
BCG 
vaccination
TST induration 
(size)
CLIA-IGRA  
result
CLIA-IGRA
Ag-NC (IU/mL)
QFT-GIT assay 
result
QFT-GIT
Ag-NC (IU/mL)
Additional information
1 53/F Yes Negative (0 mm) Negative 0.29 Positive 0.87 Newly diagnosed as having LTBI by 
QFT-GIT assay
2 46/M N/A Positive (12 mm) Negative 0.30 Positive 1.07 Normal X-ray
3 22/F Yes Positive (15 mm) Negative 0.26 Positive 3.59 Recovering from recent active TB
AFB, PCR negative
Abbreviations: M, male; F, female; BCG, Bacillus Calmette-Guérin; TST, tuberculin skin test; Ag, antigen; ANC, negative control; TB, tuberculosis infection; 
AFB, acid-fast stain; N/A, not available; CLIA-IGRA, chemiluminescent immunoanalyzer-based interferon gamma releasing assay; QFT-GIT, QuantiFERON-
TB Gold In-Tube; LTBI, latent tuberculosis infection.
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ples, we repeated both assays with the same sample and found 
agreement between the results of the initial and the second tests. 
To determine which result was consistent with the subjects’ clini-
cal diagnosis, we reviewed their medical records. The three dis-
cordant cases included an HCW diagnosed as having LTBI by 
QFT-GIT assay (subject 1) and an HCW with a resolved active 
TB infection (subject 3). The medical record of subject 2 was 
not available (Table 4). 
Correlation of IFN-γ levels from the TB antigen tube 
between CLIA-IGRA and QFT-GIT assay
A total of 303 samples with TB antigen tube results within the 
analytical range of each assay were evaluated. Thirty-eight sam-
ples with quantitative results above the analytical measurement 
range were excluded since the value above the range was not 
validated. A moderate correlation was observed between the 
IFN-γ levels in the CLIA-IGRA and QFT-GIT TB antigen tubes 
(R=0.75). In addition, the subgroup with background-corrected 
TB antigen values <5 IU/mL showed a linear regression slope 
of 0.57 (R=0.83), whereas the subgroup with values <1 IU/mL, 
near the cut-off value for diagnosing infection, showed a linear 
regression slope of 1.02 (R=0.89) (Fig. 1). 
AUC results are shown in Fig. 2. The AUC value was 1.00 
(95% CI=0.99–1.00), and the cut-off value with the maximal 
sum of sensitivity and specificity was 0.30 IU/mL (99.49% sen-
Fig. 1. Comparison of the calculated IFN-γ value of the TB antigen 
tube minus the negative control between QFT-GIT and the CLIA-IG-
RA. The correlation between the two assays was determined for 
three subgroups: samples with a calculated IFN-γ value of (A)<5 
IU/mL, (B)<2 IU/mL, and (C)<1 IU/mL. 
Abbreviations: IFN-γ, interferon gamma; TB, tuberculosis; QFT-GIT, Quan-
tiFERON-TB Gold In-Tube; CLIA-IGRA, chemiluminescent immunoanalyzer-
based IFN-γ releasing assay; R, Pearson’s correlation coefficient. 
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Fig. 2. ROC curve of the CLIA-IGRA to diagnose latent tuberculosis 
infection. Infection was assessed based on the results of the QFT-
GIT assay.
Abbreviations: AUC, area under the curve; CI, confidence interval; CLIA, 
chemiluminescent immunoanalyzer-based interferon-gamma releasing as-
say; QFT-GIT, QuantiFERON-TB Gold In-Tube.
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sitivity and 99.30% specificity). Using the manufacturer-sug-
gested cut-off value of 0.35 IU/mL, the result showed compara-
ble sensitivity (97.95%) and specificity (100.00%). 
DISCUSSION
We compared the analytical performance of CLIA-IGRA with that 
of the widely used QFT-GIT assay. Our results showed that CLIA-
IGRA detects samples with very low levels of IFN-γ (LoQ=0.25 
IU/mL) in a wide linear dilution range (0.25–200 IU/mL). This is 
in accordance with previous reports that a CLIA with magnetic 
microparticles has many advantages over ELISA [14-16].
We found a moderate correlation across the analytical mea-
surement range between the quantitative values obtained from 
both assays. In addition, we evaluated the correlation of value 
differences between the IFN-γ levels of the TB and NC tubes, 
which determine the status of infection. We found that the slope 
of the correlation model was 1.02, indicating a strong correla-
tion despite the different measuring methods of the two assays.
AUC analysis indicated the cut-off value of CLIA-IGRA (0.35 
IU/mL), which was the same as that of QFT-GIT assay, is accept-
able for application. As the same cut-off value was applied to 
CLIA-IGRA and QFT-GIT assay, there is continuity in assay re-
sults; therefore, there will be less confusion for physicians and 
technicians when they analyze the assay results.
Of the 341 samples, three were discordant (0.88%) with neg-
ative CLIA-IGRA values bordering on the 0.35 IU/mL cut-off value, 
ranging from 0.26 to 0.30 IU/mL. Subject 1 was an HCW with-
out any clinical symptoms and with a normal chest X-ray but 
was diagnosed as having LTBI solely by positive QFT-GIT assay. 
Woo, et al. [17] reported the conversion of results with border-
line range, and no other assay, such as PCR, was performed for 
this sample, so it is difficult to conclude that the negative CLIA-
IGRA result is incorrect. Subject 2 was also an HCW without 
medical records or additional laboratory results. Considering the 
positive TST induration results, the possibility of TB infection 
should be considered, although false positive results due to BCG 
vaccination cannot be excluded. As we could not evaluate the 
progress of the disease in this subject, we considered this case 
inconclusive. Subject 3 was diagnosed as having an active TB 
infection eight months prior to this study. Subject 3 received six 
months of medication, and other laboratory results, such as acid-
fast bacillus (AFB) stain and PCR, were negative, indicating com-
plete resolution of the infection. However, previous studies have 
described persistent IFN-γ response after LTBI treatment [18, 
19]. High variation between studies on IGRA reversion rates af-
ter treatment has also been reported [20, 21]; thus, the use of 
IGRA for monitoring the treatment of TB remains controversial. 
Our study had a number of limitations. The number of blood 
samples was small, and a limited number of discordant results 
was observed for the two assays. Of the three samples with dis-
cordant results, one was inconclusive owing to a lack of medical 
records. Availability of medical records with long term follow-up 
of discrepant subjects may be necessary for future studies to 
determine which of the two assays agrees with patients’ clinical 
characteristics. In addition, samples were collected from HCWs 
and patients, which could have resulted in a higher proportion 
of positive results by both assays compared with the general 
population [22, 23]. Further investigations are required to ex-
plore the usefulness of the new CLIA-IGRA in a large popula-
tion. We applied the recommended CLIA cut-off value to our 
study population, which included HCWs and patients; previous 
studies have reported the need for a higher cut-off value for IGRA 
in HCW settings [24, 25]. Therefore, future studies with a new 
cut-off value used in a large population comprising only HCWs 
are needed.
Finally, QFT-GIT assay is currently undergoing a transition to 
QuantiFERON-TB Gold Plus (QFT-Plus), with a four-sample tube 
system [26]. However, when our study was designed, QFT-GIT 
assay was widely used as a reference method; thus, we performed 
a comparison with QFT-GIT, which has the same three-tube sys-
tem as the new CLIA-IGRA, to determine the speed and conve-
nience of the new assay for providing acceptable results. Recent 
comparisons between QFT-GIT assay and QFT-Plus revealed 
that QFT-Plus shows better sensitivity in detecting recent TB con-
tact [24, 27, 28]. This is important for determining the relevance 
of CLIA-IGRA with respect to QFT-Plus in future studies.
In conclusion, automated CLIA-IGRA with the same cut-off 
value as QFT-GIT assay has continuity with existing assay results 
and comparable diagnostic performance. Thus, CLIA-IGRA can 
be a good alternative to QFT-GIT assay for LTBI diagnosis. CLIA-
IGRA has a rapid turn-around time, is user-friendly, has the op-
tion of on-site analysis, and is best suited for a small clinic setting. 
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